KR20060082037A - 퀘티아핀의 대사산물 - Google Patents

퀘티아핀의 대사산물 Download PDF

Info

Publication number
KR20060082037A
KR20060082037A KR1020057025264A KR20057025264A KR20060082037A KR 20060082037 A KR20060082037 A KR 20060082037A KR 1020057025264 A KR1020057025264 A KR 1020057025264A KR 20057025264 A KR20057025264 A KR 20057025264A KR 20060082037 A KR20060082037 A KR 20060082037A
Authority
KR
South Korea
Prior art keywords
disorders
bipolar
symptoms
depression
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057025264A
Other languages
English (en)
Korean (ko)
Inventor
제프리 골드스테인
스콧 더블유. 그림
헬렌 알. 윈터
패트리샤 씨. 데이비스
레이몬드 에프. 수코우
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20060082037A publication Critical patent/KR20060082037A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057025264A 2003-07-02 2004-06-28 퀘티아핀의 대사산물 Withdrawn KR20060082037A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
US60/484,365 2003-07-02

Publications (1)

Publication Number Publication Date
KR20060082037A true KR20060082037A (ko) 2006-07-14

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057025264A Withdrawn KR20060082037A (ko) 2003-07-02 2004-06-28 퀘티아핀의 대사산물

Country Status (20)

Country Link
US (1) US20050026900A1 (https=)
EP (1) EP1644005B1 (https=)
JP (1) JP2007516193A (https=)
KR (1) KR20060082037A (https=)
CN (1) CN1816339B (https=)
AR (1) AR045004A1 (https=)
AT (1) ATE477803T1 (https=)
AU (1) AU2004253334A1 (https=)
BR (1) BRPI0412127A (https=)
CA (1) CA2531284A1 (https=)
DE (1) DE602004028739D1 (https=)
ES (1) ES2349091T3 (https=)
IL (1) IL172616A0 (https=)
IS (1) IS8283A (https=)
MX (1) MXPA05013869A (https=)
NO (1) NO20060556L (https=)
RU (1) RU2005141060A (https=)
TW (1) TW200509944A (https=)
UY (1) UY28400A1 (https=)
WO (1) WO2005002586A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
AU2006231497A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
WO2008079848A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
WO2007062337A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Crystalline forms
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
WO2008116144A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Methods of treating mood disorders
JP2009516705A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 塩の形態
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2007062338A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010531292A (ja) * 2006-12-20 2010-09-24 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用

Also Published As

Publication number Publication date
US20050026900A1 (en) 2005-02-03
CA2531284A1 (en) 2005-01-13
NO20060556L (no) 2006-04-03
WO2005002586A8 (en) 2006-02-09
IL172616A0 (en) 2006-04-10
DE602004028739D1 (de) 2010-09-30
BRPI0412127A (pt) 2006-08-15
RU2005141060A (ru) 2006-07-27
MXPA05013869A (es) 2006-02-28
JP2007516193A (ja) 2007-06-21
IS8283A (is) 2006-02-01
AU2004253334A1 (en) 2005-01-13
WO2005002586A1 (en) 2005-01-13
TW200509944A (en) 2005-03-16
ATE477803T1 (de) 2010-09-15
EP1644005A1 (en) 2006-04-12
UY28400A1 (es) 2005-01-31
ES2349091T3 (es) 2010-12-27
AR045004A1 (es) 2005-10-12
CN1816339B (zh) 2010-12-15
CN1816339A (zh) 2006-08-09
EP1644005B1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
KR20060082037A (ko) 퀘티아핀의 대사산물
JP2008525414A (ja) 精神病性障害を治療するためのサブコメリンと神経遮断薬との組み合わせ
US20110136786A1 (en) Method of treating mood disorders
US20110144089A1 (en) Method of treating schizophrenia and other disorders
KR20050121235A (ko) 정동 장애를 치료하기 위한10-히드록시-10,11-디히드로카르바마제핀 유도체의 용도
TW201144321A (en) Benzazepine compound
US20110136784A1 (en) Method of Treating Anxiety Disorders
KR20050121236A (ko) 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도
US20050026899A1 (en) Metabolite
US20090093461A1 (en) Methods of Treating Anxiety and Mood Disorders
US20090093460A1 (en) Compositions
CA2415475C (en) Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
US20110144088A1 (en) Method of treating sleep disorders
US20100093700A1 (en) Methods of Treating Mood Disorders
JP2008526839A (ja) １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US20110136785A1 (en) Method of treatment
CN101351210A (zh) 11－哌嗪－1－基二苯并[b,f][l,4]硫氮杂卓或其药学上可接受的盐的新用途及其用于口服药物组合物的新用途
AU2001284391A1 (en) Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
EP3322422A1 (en) Heteroaryl carbonitriles for the treatment of disease
US20060229292A1 (en) Method of treating childhood disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051229

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid